Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $84.00 | Overweight | Piper Sandler |
| 2/7/2025 | $91.00 | Overweight | Wells Fargo |
| 11/21/2024 | $73.00 | Buy | Goldman |
| 10/24/2024 | $72.00 | Buy | UBS |
| 3/28/2024 | $69.00 | Buy | Truist |
| 3/4/2024 | $42.00 → $65.00 | Buy | Needham |
| 11/2/2023 | $45.00 | Buy | Canaccord Genuity |
| 8/21/2023 | Outperform | TD Cowen |
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr
SC 13G/A - Merus N.V. (0001651311) (Subject)
SC 13G/A - Merus N.V. (0001651311) (Subject)
SC 13G/A - Merus N.V. (0001651311) (Subject)
4 - Merus N.V. (0001651311) (Issuer)
4 - Merus N.V. (0001651311) (Issuer)
4 - Merus N.V. (0001651311) (Issuer)
Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00
Wells Fargo initiated coverage of Merus with a rating of Overweight and set a new price target of $91.00
Goldman initiated coverage of Merus with a rating of Buy and set a new price target of $73.00
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. About M
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 - Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's
PRE 14A - Merus N.V. (0001651311) (Filer)
SCHEDULE 13G - Merus N.V. (0001651311) (Subject)
10-K/A - Merus N.V. (0001651311) (Filer)
For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 - Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 - Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a July 5, 2024 data cutoff from the ongoing phase 1/2 trial of petosemtamab, a Biclonics® tar
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)